Niagen Bioscience (NAGE) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended September 2025. This widely-known ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029402721/en/ The articles, information, and content displayed on this webpage ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from SinoMab Bioscience ...

In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging.

PURE Bioscience, Inc., creator of the patented non-toxic silver dihydrogen citrate antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2025. Net product ...

Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial performance for the ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...

– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent ...

Artelo Biosciences ( (ARTL)) has released its Q3 earnings. Here is a breakdown of the information Artelo Biosciences presented to its investors. Artelo Biosciences, Inc. is a clinical-stage ...

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher ...